Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study

Karen Ho, Kris M. Jamsen, J. Simon Bell, Maarit Jaana Korhonen, Kevin P. Mc Namara, Dianna J. Magliano, Danny Liew, Taliesin E. Ryan-Atwood, Jonathan E. Shaw, Susan Luc, Jenni Ilomäki

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Purpose: Clinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia. Methods: Data from the Australian Diabetes, Obesity and Lifestyle study collected in 2011–2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by > 50, 30–50, and < 30%, respectively. Logistic regression was used to estimate adjusted odd ratios (ORs) and 95% confidence intervals (CIs) for factors associated with high- versus low-to-moderate-intensity statin therapy. Results: Overall, 1108 (24%) study participants used a statin. Data on statin intensity were available for 1072 participants. The proportions of high-, moderate-, and low-intensity statin therapy were 32 (n = 341), 65 (n = 696), and 3% (n = 35), respectively. Overall, 51% of people with prior cardiovascular disease (CVD) used a high-intensity statin. In addition to prior CVD (OR = 3.34, 95% CI = 1.95–5.73), no (OR = 1.84, 95%CI 1.02–3.31) or insufficient physical activity (OR = 1.51, 95% CI = 1.01–2.25), obesity (OR = 1.87, 95% CI = 1.13–3.10), and consuming > 2 alcoholic drinks daily (OR = 1.66, 95% CI = 1.08–2.55) were associated with high versus low-to-moderate-intensity statin therapy. Conversely, age 65–74 vs. < 65 years was inversely associated with high-intensity statin therapy (OR = 0.62, 95% CI = 0.41–0.94). Conclusions: Prior CVD was the strongest factor associated with high-intensity statin therapy. Although the prevalence of CVD increases with age, older people were less likely to be treated with high-intensity statins.

Original languageEnglish
Pages (from-to)1493-1501
Number of pages9
JournalEuropean Journal of Clinical Pharmacology
Volume74
Issue number11
DOIs
Publication statusPublished - 1 Nov 2018

Keywords

  • Australia
  • Cardiovascular disease
  • Cholesterol
  • Epidemiology
  • HMG-CoA reductase inhibitors

Cite this